Modulation of TSP-1 expression in RA synovial tissue can be achieved in vivo through TNFi therapy effects on transcriptional networks including NR4A2 activity, suggesting that altered TSP-1 levels early in disease may be beneficial, leading to inflammatory resolution (56). Here, NR4A2 is linked to rheumatoid arthritis.